Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 6/20 | 0.33 |
| ▸ | NPY1R | P25929 | 4/20 | 0.33 |
| ▸ | NPY2R | P49146 | 3/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.33 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192303 | 0.94 | NPY4R (0.36) | NPY4RNPY1RNPY2RNPY5RDPP4 | |
| SCHEMBL2194721 | 0.87 | BACE1 (0.36) | NPY4RNPY1RNPY2RNPY5RDPP4 | |
| SCHEMBL2181812 | 0.87 | BACE1 (0.34) | KISS1RBACE1 | |
| SCHEMBL9409322 | 0.85 | CTSC (0.34) | — | |
| SCHEMBL2159226 | 0.83 | NPY4R (0.50) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30656926 | 0.82 | MMP2 (0.40) | KISS1RBACE1 | |
| SCHEMBL30656920 | 0.82 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL30728878 | 0.82 | MME (0.43) | NPY4RNPY1RNPY2R | |
| SCHEMBL2193343 | 0.81 | BACE1 (0.45) | BACE1 | |
| SCHEMBL16468661 | 0.80 | CTSC (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | NPY4R 567/4885NPY1R 544/4885NPY2R 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.